Our studies demonstrate the importance of adipose tissue-liver crosstalk in mediating MASLD progression and identify adipocyte IL-6-gp130 as a potential therapeutic target. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.